Literature DB >> 17724073

Antigen-specific cellular and humoral responses are induced by intradermal Mycobacterium leprae infection of the mouse ear.

Malcolm S Duthie1, Stephen T Reece, Ramanuj Lahiri, Wakako Goto, Vanitha S Raman, Juliette Kaplan, Greg C Ireton, Sylvie Bertholet, Thomas P Gillis, James L Krahenbuhl, Steven G Reed.   

Abstract

Leprosy is caused by infection with Mycobacterium leprae. The immune response of leprosy patients can be highly diverse, ranging from strong cellular responses accompanied by an apparent deficit of M. leprae-specific antibodies to strong humoral responses with a deficit of cell-mediated responses. Leprosy takes many years to manifest, and this has precluded analyses of disease and immune response development in infected humans. In an attempt to better define development of the immune response during leprosy we have developed an M. leprae ear infection model. Intradermal inoculation of M. leprae into the ear supported not only infection but also the development of a chronic inflammatory response. The inflammatory response was localized, comprising a T-cell infiltration into the ear and congestion of cells in the draining lymph nodes. The development of local chronic inflammation was prevented by rifampin treatment. Importantly, and in contrast to subcutaneous M. leprae footpad infection, systemic M. leprae-specific gamma interferon and antibody responses were detected following intradermal ear infection. These results indicate the utility of intradermal ear infection for both induction and understanding of the immune response during M. leprae infection and the identification or testing of new leprosy treatments.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17724073      PMCID: PMC2168264          DOI: 10.1128/IAI.00564-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

1.  Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy.

Authors:  Emmanuelle Cambau; Pascale Bonnafous; Evelyne Perani; Wladimir Sougakoff; Baohong Ji; Vincent Jarlier
Journal:  Clin Infect Dis       Date:  2001-11-21       Impact factor: 9.079

2.  Multiplication of Mycobacterium leprae in the foot-pad of the mouse.

Authors:  C C SHEPARD
Journal:  Int J Lepr       Date:  1962 Jul-Sep

3.  Global leprosy situation, 2005.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2005-08-26

4.  Rifampicin/minocycline and ofloxacin (ROM) for single lesions--what is the evidence?

Authors:  D N Lockwood
Journal:  Lepr Rev       Date:  1997-12       Impact factor: 0.537

5.  Bactericidal activities of R207910 and other newer antimicrobial agents against Mycobacterium leprae in mice.

Authors:  Baohong Ji; Aurélie Chauffour; Koen Andries; Vincent Jarlier
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

6.  Reconstitution of Mycobacterium leprae immunity in severe combined immunodeficient mice using a T-cell line.

Authors:  N Azouaou; R H Gelber; K Abel; D T Sasaki; L P Murray; R M Locksley; N Mohagheghpour
Journal:  Int J Lepr Other Mycobact Dis       Date:  1993-09

7.  Anatomical mapping of epidermal Langerhans cell densities in adults.

Authors:  B Berman; V L Chen; D S France; W I Dotz; G Petroni
Journal:  Br J Dermatol       Date:  1983-11       Impact factor: 9.302

8.  Strain variations in the murine cellular immune response to the phenolic glycolipid I antigen of Mycobacterium leprae.

Authors:  F T Koster; C Teuscher; P Matzner; E Umland; D Yanagihara; P J Brennan; K S Tung
Journal:  Infect Immun       Date:  1986-02       Impact factor: 3.441

9.  Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients.

Authors:  Roland V Cellona; Maria F V Balagon; Eduardo C dela Cruz; Jasmin A Burgos; Rodolfo M Abalos; Gerald P Walsh; Richard Topolski; Robert H Gelber; Douglas S Walsh
Journal:  Int J Lepr Other Mycobact Dis       Date:  2003-12

10.  The site of Leishmania major infection determines disease severity and immune responses.

Authors:  Tracey M Baldwin; Colleen Elso; Joan Curtis; Lynn Buckingham; Emanuela Handman
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

View more
  4 in total

1.  Protection against Mycobacterium leprae infection by the ID83/GLA-SE and ID93/GLA-SE vaccines developed for tuberculosis.

Authors:  Malcolm S Duthie; Rhea N Coler; John D Laurance; Lucas H Sampaio; Regiane M Oliveira; Ana Lucia M Sousa; Mariane M A Stefani; Yumi Maeda; Masanori Matsuoka; Masahiko Makino; Steven G Reed
Journal:  Infect Immun       Date:  2014-07-14       Impact factor: 3.441

Review 2.  Advances and hurdles on the way toward a leprosy vaccine.

Authors:  Malcolm S Duthie; Thomas P Gillis; Steven G Reed
Journal:  Hum Vaccin       Date:  2011-11-01

3.  A Mouse Model of Ulcerative Cutaneous Leishmaniasis by Leishmania (Viannia) panamensis to Investigate Infection, Pathogenesis, Immunity, and Therapeutics.

Authors:  Natalia Muñoz-Durango; Alexander Gómez; Natalia García-Valencia; Miguel Roldán; Marcela Ochoa; David E Bautista-Erazo; José R Ramírez-Pineda
Journal:  Front Microbiol       Date:  2022-06-13       Impact factor: 6.064

4.  Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection.

Authors:  Vanitha S Raman; Joanne O'Donnell; H Remy Bailor; Wakako Goto; Ramanuj Lahiri; Thomas P Gillis; Steven G Reed; Malcolm S Duthie
Journal:  Infect Immun       Date:  2009-09-28       Impact factor: 3.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.